Recombinant mouse GM-CSF protein

GM-CSF is a hematopoietic growth factor that stimulates the development of neutrophils and macrophages and promotes the proliferation and development of early erythroid megakaryocytic and eosinophilic progenitor cells. It is produced in by endothelial cells, monocytes, fibroblasts and T-lymphocytes. GM-CSF inhibits neutrophil migration and enhances the functional activity of the mature end-cells. Mouse GM-CSF protein is 125 amino acids and shares approximately 60% homology with the human GM-CSF protein. Recombinant mouse GM-CSF was expressed in E. coli and purified by conventional chromatography, after refolding of the isolated inclusion bodies in a renaturation buffer

Product Specifications

Specifications

Mouse GM-CSF stimulates cell proliferation of the MC/9 mouse mast cells. The ED50 range is less or equal 0.06 ng/mL.

Product Name Alternative

Granulocyte-macrophage colony stimulating factor 2, Csf2, Csfgm, MGI-IGM, mGM-CSF, Granulocyte-macrophage colony stimulating factor 2, Granulocyte-macrophage colony stimulating factor 2

Expression System

E.coli

Antigen Species

Mouse

Tag

Non-Tagged

Applications

SDS-PAGE, Bioactivity

Concentration

1 mg/mL (determined by BCA assay)

Endotoxin

< 1 EU per 1ug of protein (determined by LAL method)

Purity

> 95% by SDS-PAGE

Bioactivity

Measured in a cell proliferation assay using MC/9 mouse mast cells. The ED50 for this effect is less or equal to 0.06 ng/mL.

Molecular Weight

14 kDa (125aa) confirmed by MALDI-TOF

Additionnal Information

GM-CSF, MSF0801-10 µg, MSF0801-20 µg, MSF0801-50 µg, MSF0801-100 µg, MSF0801-250 µg, MSF0801-500 µg, MSF0801-1 mg, MSF0801-10, MSF0801-20, MSF0801-50, MSF0801-100, MSF0801-250, MSF0801-500, MSF0801-1

References & Citations

Fleetwood AJ., et al , (2005) . Crit Rev Immunol. 25 (5) :405-28.; ; Hamilton JA., et al. (2004) . Growth Factors. 22 (4) :225-31.;

Other References

Hotta M, et al. GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells. Eur J Immunol. 2019 Jan;49 (1) :179-191.{https://pubmed.ncbi.nlm.nih.gov/30457669/}; ; Tsubokura Y, et al. Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract. (Immun Inflamm Dis. 2022 Sep) {https://pubmed.ncbi.nlm.nih.gov/36039651/}